Raymond James Financial’s Black Diamond Therapeutics BDTX Stock Holding History

Raymond James Financial’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.1K	Buy	14,115 +647	+5%	+$1.54K	﹤0.01%	5172
2025 Q4	$32.7K	Sell	13,468 -3,747	-22%	-$13.3K	﹤0.01%	5045
2025 Q3	$65.2K	Sell	17,215 -19,673	-53%	-$57.5K	﹤0.01%	4799
2025 Q2	$91.5K	Buy	36,888 +3,464	+10%	+$6.68K	﹤0.01%	4919
2025 Q1	$51.8K	Buy	33,424 +8,432	+34%	+$17.7K	﹤0.01%	4637
2024 Q4	$53.5K	Buy	+24,992	New	+$71.6K	﹤0.01%	4601

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Raymond James Financial's BDTX Position: Q1 2026 in Review

Raymond James Financial increased its Black Diamond Therapeutics (BDTX) stake by 4.8% in Q1 2026, buying an estimated $1.54K and bringing the position to 14,115 shares worth $30.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5172.

Raymond James Financial first reported a position in BDTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $91.5K in Q2 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Raymond James Financial held 14,115 shares of Black Diamond Therapeutics worth $30.1K as of Q1 2026.
Raymond James Financial bought 647 Black Diamond Therapeutics shares in Q1 2026, an estimated $1.54K.
Black Diamond Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5172 holding.
Raymond James Financial first reported a position in Black Diamond Therapeutics in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Black Diamond Therapeutics position peaked at $91.5K in Q2 2025.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.